BioAtla, Inc. (NASDAQ: BCAB) announced today, October 20, 2025, that it has presented preliminary clinical data from its Phase 1 study of BA3182 at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin. The data were shown in a poster titled “Preliminary Results from a First‑in‑Human Phase 1 Study of BA3182, a Dual‑Conditionally Binding Biologic (CAB) EpCAM × CD3 Bispecific T‑cell Engager in Patients with Treatment‑Refractory Metastatic Adenocarcinoma,” and the poster was featured in the Investigational Immunotherapy session on Sunday, October 19.
BA3182 is a dual‑conditionally binding bispecific T‑cell engager that targets EpCAM and CD3, designed to bind selectively within the acidic tumor microenvironment and thereby reduce on‑target, off‑tumor toxicity. The platform is intended to treat adenocarcinomas of the colon, stomach, pancreas, biliary tract, lung, breast, prostate, and thyroid, with a potential patient population of over one million patients worldwide.
CEO Jay M. Short said the data demonstrate encouraging preliminary prolonged tumor control and a manageable safety profile. He emphasized that the CAB technology multiplies binding selectivity, directing T‑cells to kill cancer cells while protecting healthy tissues, and highlighted the product’s promise across a broad range of adenocarcinomas.
The announcement of these early clinical results marks a significant operational milestone for BioAtla, providing the first evidence of BA3182’s safety and activity in humans and setting the stage for future development and potential partnership opportunities.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.